You are here

Prices & Quotes - UK Markets - Oxford Biomedica (OXB)

Risk Warning The value of investments can fall as well as rise and any income from them is not guaranteed and you may get back less than you invested. Past performance is not a guide to future performance.

Share Price:
Down 1,024.00p
Change Today:
-18.00p
Market Cap:
843.98m
Sector:
Pharmaceuticals & Biotechnology

Oxford Biomedica swings to EBITDA profit

By Josh White

Date: Thursday 15 Apr 2021

LONDON (ShareCast) - (Sharecast News) - Oxford Biomedica reported a 37% improvement in total revenues in its preliminary results on Thursday, to 87.7m.
The FTSE 250 company said bioprocessing and commercial development revenues increased 45% to 68.5m for the year ended 31 December, with double digit growth across both activities, driven by new customers AstraZeneca, Beam Therapeutics and Juno/BMS.

Revenues from licences, milestones and royalties increased to 19.2m from 16.8m in the prior year, due to the recognition of a 7.8m licence fee from Juno/BMS as well as other licence fees, milestones and royalties from customers.

Operating expenses increased by less than revenues, rising 23% to 51.7m, aided by the move to the lower-cost bioreactor manufacturing process.

The firm swung to an operating EBITDA profit of 7.3m from a loss of 5.2m in 2019, which was marginally above its guided range.

Its operating loss, meanwhile, narrowed to 5.7m from 14.5m.

The company's platform segment generated an operating profit of 2m, compared to a 20.2m loss a year earlier, while the product segment made a loss of 7.7m, swinging from a 5.7m profit in 2019.

Capital expenditure decreased to 13.4m from 25.8m, which the board said was primarily due to the Windrush Court laboratory conversion and equipment purchases, and leasehold improvements at Oxbox.

Cash at year-end stood at 46.7m, up from 16.2m at the end of 2019, and had reached 65.9m by 31 March.

Oxford Biomedica said cash used in operations totalled 3.9m for the year, falling from 6.6m as a result of the increased revenues, offset by further operational investments.

The company undertook a successful 38.3m equity fundraise in June, to exploit the growth in the cell and gene therapy market.

"We not only secured major new partnerships, brought the Oxbox manufacturing facility online in record time and responded to the challenges of the pandemic, but the team has also been able to rapidly work with AstraZeneca to provide a vaccine solution for Covid-19," said chief executive officer John Dawson.

"This is a true testament to the world-class calibre and dedication of our staff in the year that the group also gained entry to the FTSE 250.

"Looking to the future, with the continued tide of growth in cell and gene therapy, coupled with the group's leadership position in the lentiviral vector field, we are well positioned to advance both our own proprietary pipeline and that of our current and future partners' programmes."

At 0844 BST, shares in Oxford Biomedica were up 0.43% at 1,044.48p.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

OXB Market Data

Currency UK Pounds
Price 1,024.00p
Change Today -18.00p
52 Week High 1,110.00p
52 Week Low 701.00p
Volume 120,082
Shares Issued 82.42m
Market Cap 843.98m
Beta 0.00

Performance Indicators

Compare performance with the sector and the market.

Key
Vs Market
Vs Sector
Value
market
  1. half market star
  2. empty market
  3. empty market
  4. empty market
  5. empty market
sector
  1. full sector star
  2. empty sector
  3. empty sector
  4. empty sector
  5. empty sector
Price Trend
market
  1. full market star
  2. full market star
  3. full market star
  4. empty market
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. half sector star
  4. empty sector
  5. empty sector
Income
Not Available
Growth
market
  1. full market star
  2. full market star
  3. full market star
  4. half market star
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. empty sector
  5. empty sector
Price Chg 6m
market
  1. full market star
  2. full market star
  3. half market star
  4. empty market
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. half sector star
  4. empty sector
  5. empty sector
P/E
Not Available
PEG
market
  1. full market star
  2. full market star
  3. full market star
  4. empty market
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. half sector star
  5. empty sector
Dividend Yield
Not Available
EPS Growth
Not Available
Operating Margin
market
  1. full market star
  2. half market star
  3. empty market
  4. empty market
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. half sector star
  4. empty sector
  5. empty sector

What The Brokers Say

Strong Buy 3
Buy 0
Neutral 1
Sell 0
Strong Sell 1
Total 5
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

OXB Dividends

No dividends found

Trades for 07-May-2021

Time Volume / Share Price
16:39 2,000 @ 1,024.00p
16:39 2,000 @ 1,024.00p
16:35 16,797 @ 1,024.00p
16:29 56 @ 1,022.00p
16:29 21 @ 1,024.00p

OXB Key Personnel

CEO John Dawson
CFO Stuart Paynter